Carpal Tunnel Syndrome in Pediatric Mucopolysaccharidoses
Children’s Neurosciences Centre, Royal Children’s Hospital; 50
Flemington Road, Parkville, Victoria 3052. Australia
Department of Paediatrics University of Melbourne; Royal
Children’s Hospital, 50 Flemington Road, Parkville, Victoria
3052
Metabolic Unit, Victorian Clinical Genetics Service, Murdoch
Childrens Research Institute
Metabolic Unit, Victorian Clinical Genetics Service, Murdoch
Childrens Research Institute
Department of Paediatrics University of Melbourne; Royal
Children’s Hospital, 50 Flemington Road, Parkville, Victoria
3052
Corresponding author
Monique Ryan
Email : Monique.ryan@rch.org.au
Phone: +61 3 9345 5661
Abstract
Background:Carpal tunnel syndrome (CTS) is rare
in children but is a recognised complication of the
mucopolysaccharidoses (MPS). Clinicians should have a low
threshold of suspicion for CTS in patients with MPS, as their
symptoms may be atypical or minimal. If untreated, CTS can cause
significant loss of hand function. We present findings in 11
children with mucopolysaccharidoses and suspected CTS and propose
guidelines for screening for CTS in children with these disorders.
Method:Clinical and electrodiagnostic data of 11
children with mucopolysaccharidoses, suspected on clinical grounds
to have CTS, was reviewed. All subjects underwent motor and
sensory conduction studies of bilateral median and ulnar nerves.
The presence of carpal tunnel syndrome and its severity was
determined. Subsequent details regarding interventions and
recurrence were noted.
Results:Three children had MPS I, five had MPS
II, one had MPS III, and two had MPS IV. Seven had motor symptoms
and three had sensory symptoms referable to median nerve
compression. Nine of the eleven children (2 out of 3 with MPS I, 5
out of 5 with MPS II, 0 out of 1 with MPS III, 2 out of 2 with MPS
IV) had median neuropathies at the wrist, (eight bilateral, one
unilateral) which were mild in three, moderate in five, and severe
in one. Three children presented with symptoms at five years of
age. Six underwent median nerve decompression. Four of these had
recurrent symptoms several years after surgery that were
associated with changes in nerve conduction in two cases. To the
best of our knowledge, this is the first report of carpal tunnel
syndrome in MPS IV.
Conclusion:Some children with
mucopolysaccharidoses experience early development of at least
moderately severe carpal tunnel syndrome. We recommend screening
for median neuropathies at the wrist starting at age four for
children with mucopolysaccharidoses, particularly types I, II, and
IV, regardless of their symptoms of CTS and of the treatment
received for mucopolysaccharidosis.
Keyword:mucopolysaccharidosis; carpal tunnel syndrome; pediatric screening
©2015 Jadhav et al.; licensee JICNA
Background
Median neuropathy due to compression at the wrist, or carpal
tunnel syndrome (CTS), is rare in children and, when present, is
usually secondary to an underlying disorder. Previous reports have
shown that the most common cause of CTS in children are lysosomal
storage disorders, particularly the mucopolysaccharidoses (MPS)
and mucolipidoses (ML) [1,2]. The mucopolysaccharidoses are a
group of inborn errors of metabolism characterised by deficiency
of a specific lysosomal enzyme, with resulting intra-cellular
accumulation of various glycosaminoglycans leading to progressive
tissue damage. Based on the specific enzyme deficiency, seven
distinct types of MPS are known [3, 4] with several common
features but variable severity [Table 1].
Carpal tunnel syndrome often presents in an atypical way in
children. In contrast to adults with compressive median
neuropathies at the wrist, many authors report lack of complaints
of numbness, tingling, nocturnal pain, and absence of Tinel's and
Phalen's signs in children [5, 6, 7, 8]. In those with underlying
cognitive impairment, it becomes additionally important to
recognize subtle symptoms such as decreased sweating, nocturnal
waking (which is a feature of MPS), gnawing of hands, withdrawal
of hands from touch of others, manual clumsiness, alterations in
grasp or playing pattern, and increasing difficulties with fine
motor tasks, which may be associated with classical signs of
finger pulp atrophy (atrophy of the soft tissue on the palmar
surface of distal phalanx of the thumb and index finger), wasting
of the thenar eminence, and weakness of thumb abduction and
opposition [5,6,8].
Treatment options for MPS, including bone marrow transplantation
and enzyme replacement therapy, have altered the natural
progression of the disease in those affected and have placed
additional emphasis on improving quality of life. The need to
address the musculoskeletal complications of these disorders is
evident, as they can cause significant morbidity if untreated.
When severe, CTS can be quite debilitating in limiting hand
function and causing severe neuropathic pain. However, when
diagnosed and treated early, CTS generally leaves no residual
deficits.
Type of MPS
|
Deficient enzyme
|
Clinical features
|
MPS I (Hurler, Scheie, Hurler/Scheie syndrome)
|
α-L-iduronidase |
Spectrum from clinically severe to mild forms Variable
mental retardation, coarse facial features, macroglossia,
corneal clouding, hepatosplenomegaly, herniae and
dysostosis multiplex
|
MPS II (Hunter syndrome) |
Iduronate sulfatase |
Severe and mild forms Similar clinical presentation to MPS
I except for absence of corneal clouding
|
MPS III (Sanfilippo syndrome)
|
Glucosaminidase |
Prominent neurocognitive deficits (developmental
regression, hyperactivity) Minimal musculoskeletal
problems
|
MPS IV (Morquio syndrome) |
Galactosidase |
Severe skeletal dysplasia, short stature
|
MPS VI (Maroteaux-Lamy syndrome)
|
N-acetyl-galactosamine sulfatase
|
Variable (mild to severe) skeletal dysplasia, short
stature, heart defects Normal neurocognitive function
|
MPS VII (Sly syndrome) |
β glucuronidase |
Skeletal dysplasia, hepatomegaly, developmental delay,
corneal clouding
|
MPS IX |
Hyaluronidase |
Peri-articular nodular painful masses, mild facial
features, normal intelligence
|
Table 1 :The Mucopolysaccharidoses
The association between MPS and pediatric CTS has been
recognised for many years, but there are no established
guidelines for neurophysiologic screening in these conditions.
We report neurophysiologic findings in 11 children with MPS
assessed at a single tertiary centre and propose guidelines for
neurophysiologic screening in children with these conditions.
Method
This was a retrospective study in which clinical and
electrodiagnostic data of children with mucopolysaccharidoses
attending a single tertiary referral centre between the years
2001-2012 was reviewed. All children had a mucopolysaccharidosis,
with diagnosis based on urine metabolic screens, analysis of
enzyme activity in blood, or fibroblasts and/or mutation testing.
All were suspected to have carpal tunnel syndrome based on the
history of a recent onset of loss of hand function, clawing of
hands, and/or sensory features. A detailed history, including type
of MPS, treatment received for MPS, symptoms suggestive of median
nerve compression, age of first presentation with these symptoms,
surgical intervention for CTS, recurrence of symptoms, and
subsequent management, was noted.
All subjects underwent nerve conduction studies using a Dantec
system. Sensory studies were performed by stimulating the median
and ulnar nerves orthodromically in the mid-palm at a distance of
7 cm distal to the wrist recording electrodes with application of
supramaximal stimulus of 0.1 ms duration. The latency to onset,
peak to peak amplitude, and sensory conduction velocity was
measured. The values obtained on both motor and sensory studies
were compared with the normal reference values for digital studies
in children and adolescents of comparable ages, as normal values
for palmar studies were not available [9]. An abnormal sensory
response was identified where there was an absent or low amplitude
median sensory action potential and/or a prolonged absolute median
sensory latency and/or a median- ulnar latency difference of >0.3
ms [10] . The median and ulnar motor responses were recorded with
surface electrodes over the abductor pollicis brevis and abductor
digiti minimi, respectively, after giving a supramaximal stimulus
at the wrist and elbow. The distal motor latency, peak compound
muscle action potential (CMAP), amplitude, and motor conduction
velocity was measured. The presence of a prolonged distal median
motor latency, with and without low amplitude or absent median
compound motor action potential, was considered to be an abnormal
motor response. The electrodiagnostic data was then analysed to
determine the presence or absence of median neuropathy at the
wrist and, where present, its severity was determined using the
following neurophysiologic criteria based on the scale proposed by
the American Association of Neuromuscular and Electrodiagnostic
Medicine [11]:
Treatment options for MPS, including bone marrow transplantation
and enzyme replacement therapy, have altered the natural
progression of the disease in those affected and have placed
additional emphasis on improving quality of life. The need to
address the musculoskeletal complications of these disorders is
evident, as they can cause significant morbidity if untreated.
When severe, CTS can be quite debilitating in limiting hand
function and causing severe neuropathic pain. However, when
diagnosed and treated early, CTS generally leaves no residual
deficits.
-
* Mild – Prolonged (relative or absolute)
sensory latencies with normal motor studies. No evidence of axon
loss.
-
* Moderate – Abnormal median sensory latencies and
prolongation of median motor distal latency. No evidence of axon
loss.
-
* Severe – Any of the above features with evidence of
axon loss as defined by either a) an absent or low amplitude
SNAP, b) a low amplitude or absent median CMAP, or c) a needle
EMG with fibrillation potentials or motor unit potential changes
(where performed).
Some patients then underwent decompression surgery of the median
nerve based on the clinical symptoms and severity of median
neuropathy on the neurophysiologic studies. The subsequent
clinical course and findings on repeat nerve conduction study,
where performed, were noted.
Subject |
Diagnosis (syndrome) |
Age at presentation with CTS (y) |
Sensory latency (ms)/ SNAP amplitude (μV) |
Distal motor latency (ms)/ CMAP amplitude (mV) |
Median-Ulnar sensory latency difference (ms) |
|
|
|
Right |
Left |
Right |
Left |
|
1 |
Morquio |
15 |
3.2/27.8 |
3.3/22.4 |
2.5/8.0 |
2.5/7.6 |
0.2 L, 0.4 R |
2 |
Morquio |
12 |
0.8/190 |
1.0/110 |
0.8/8.0 |
1.7/9.2 |
0.4 L, 0.2 R |
3 |
Hunter |
10 |
Absent |
Absent |
3.3/6.4 |
2.7/0.7 |
Absent |
4 |
Hunter |
5 |
3.4/29.2 |
0.8/54.2 |
4.2/4.7 |
5.8/3.6 |
0.2 L, 1.6 R |
5 |
Hunter |
5 |
1.0/12.4 |
1.0/31.9 |
3.3/3.7 |
5.0/4.8 |
0.3 L, 0.4 R |
6 |
Hurler |
10 |
Absent |
Absent |
3.5/7.8 |
4.1/8.3 |
Absent |
7 |
Hurler |
5 |
4.2/27 |
3.75/83 |
4.2/3.2 |
3.3/6.6 |
0.25L, 0.7 R |
8 |
Sanfilippo |
15 |
0.9/30 |
0.8/66.2 |
1.2/10.3 |
1.4/8.9 |
0.1 L, 0.2 R |
9 |
Hunter |
12 |
Absent |
Absent |
0.9/9.5 |
1.3/10.2 |
Absent |
10 |
Hurler |
8 |
1.0/30.5 |
1.52/45.8 |
2.4/9.5 |
2.17/9.7 |
0.2 L, 0.2 R |
11 |
Hunter |
8 |
4.1/12.9 |
4.0/12.3 |
1.67/0.3 |
1.67/0.6 |
1.2 L, 0.9R |
Table 2: Sensory and Motor Nerve Conduction Findings in Children with MPS Abnormal values are highlighted in bold [9].
Results
Eleven boys with MPS, aged 5 to 17 years old, were studied. Three had Hurler syndrome (MPS I), five had Hunter syndrome (MPS II), one had Sanfilippo syndrome(MPS III), and two had Morquio syndrome (MPS IV). The mean age of presentation with symptoms referable to CTS was 9.5 years (range 5-15 years) with three children presenting at 5 years of age.
The most common symptom, noted in seven children, was a loss of hand function characterized by difficulty writing and loss of fine motor function associated with wasting of the thenar muscles. Sensory features ,hand numbness and pain, were present in one subject with MPS IV, while one child with MPS II had only numbness of both hands. One child with MPS I syndrome presented with a history of persistent gnawing at his fingers and had mild clawing of both hands. The only patient with Sanfilippo syndrome (MPS III) had decreased sensation over the right hand in the radial distribution with a previous history of right radial nerve palsy secondary to a supracondylar fracture of the humerus with no other symptoms directly referable to CTS.
Two children (one with MPS I and one with MPS II) were receiving enzyme replacement therapy for 1 and 4 years, respectively, before presenting with symptoms of median nerve compression. One child with MPS I had undergone bone marrow transplantation at 17 months of age before presenting with symptoms of median neuropathy at 5 years old. Two children were started on enzyme replacement therapy three years after bilateral surgical median nerve decompression for moderate CTS but had recurrence of clinical symptoms of CTS, having been on enzyme replacement therapy for more than six years.
On nerve conduction studies, nine of the eleven patients studied (two with MPS IV, five with MPS II, and two with MPS I) had neurophysiologic evidence of median neuropathy at the wrist based on absent or prolonged median sensory latencies, prolonged distal motor latencies, or low amplitude of median CMAPs [Table 2]. In patients with mild changes, only the median sensory responses were abnormal. Of these nine subjects, eight had bilateral changes while one had only unilateral CTS. Three had mild, five had moderate, and one had severe CTS. Electromyography was not performed on any of the subjects.
Six subjects with either moderate or severe CTS underwent surgical decompression of the median nerves on both hands (patients 3, 4, 5, 6, 7, and 11). Two underwent surgery at age 5 years old with no subsequent recurrence (patients 4 and 5). The remaining four, who underwent surgery between ages 7 and 10 years old with initial clinical recovery, had subsequent recurrence of symptoms of CTS 5, 7, 8, and 10 years after surgery, respectively (patients 3, 6, 7, and 11). Two of these subjects received enzyme replacement therapy for more than six years before the recurrence. Three of those with recurrent symptoms underwent repeat nerve conduction studies, of whom two had neurophysiologic evidence of CTS – moderate unilateral in one (patient 6) and mild bilateral in the other (patient 11). To date, no subjects have undergone repeat surgery.
Discussion
Carpal tunnel syndrome has been reported in association with the storage disorders MPS I, MPS II, MPS VI, and mucolipidoses II and III [12, 13] . It has a reported eventual prevalence of over 90% in MPS types I and II [14]. Development of CTS in MPS is thought to result from excessive deposition of glycosaminoglycans within the flexor retinaculum along with dysplasia of the underlying bones, causing compression of the median nerve in the carpal tunnel. Mucolipidoses are also a common cause of childhood CTS [2]. The clinical features of mucolipidoses mimic those of some of the mucopolysaccharidoses [7]. CTS is sometimes the first presenting feature of type III mucolipidosis, which is also known as pseudo-Hurler syndrome [15]. Carpal tunnel syndrome is only rarely seen in MPS III (Sanfilippo syndrome) [16]. The present series includes subjects with a variety of mucopolysaccharidoses but no mucolipidoses. The only subject with Sanfilippo syndrome was suspected to have CTS but had normal nerve conduction studies. Two subjects with MPS IV in this study had CTS. To our knowledge, this is the first report of this association in MPS IV (Morquio syndrome).
Children with MPS may have very early compression of their median nerves, often presenting before five years of age. Bona et al reported four children with MPS (two with MPS I and two with MPS II) who presented before 5 years of age with bilateral claw hands and were diagnosed with CTS on the basis of median nerve conduction studies and electromyography [17]. In the present study, three children (two with MPS II and one with MPS I) were diagnosed with moderate CTS affecting both hands at 5 years of age and requiring surgical release.
Classical symptoms suggesting CTS in adults, such as nocturnal paresthesias, pain, or sensory disturbance over the hands, are rare in children [8]. Moreover, children with MPS who have intellectual disability may find it difficult to localise and describe their symptoms. Signs of median nerve compression, such as wasting of thenar muscles, decreased hand function, and clawing of the fingers, are the main presenting features in children. In one large series of 42 MPS patients, specific symptoms of CTS were much less common than relatively non-specific complaints, such as decreased sweating, pulp atrophy (defined as atrophy of the soft tissue on the palmar surface of distal phalanx of the thumb and index finger), thenar muscle wasting, and manual clumsiness [18] . Another study identified difficulty in fine motor tasks as the most frequent complaint in childhood CTS [19]. These signs develop only when axon loss has occurred, and hence are seen only late in the course of compressive median neuropathies. Sensory symptoms, such as gnawing of the hands, were seen in a minority of children in this series with most subjects presenting with decreased hand function and clawing of the hands. These findings can develop in MPS syndromes independent of CTS as a result of bone and soft tissue involvement. The frequency of atypical clinical presentations of CTS in children with MPS, coupled with their lack of expression of symptoms in those with intellectual disability, increases the importance of having a low threshold for suspicion and early screening for CTS in children affected by these conditions.
Enzyme replacement therapy and bone marrow transplant for MPS do not prevent development of CTS in those children who already have bone abnormalities as part of their disease. There is insufficient data to comment on the effect of enzyme therapy for MPS in prevention of bone abnormalities and carpal tunnel syndrome if treatment is started from birth. Field and colleagues reported musculoskeletal development in 12 children with Hurler syndrome who underwent bone marrow transplantation before two years of age [20]. All twelve children developed progressive thoracolumbar kyphosis and hip subluxation, while seven developed carpal tunnel syndrome more than five years after the transplant. Surgical decompression for CTS was needed in all affected children at an average age of 112 months. The authors concluded that the benefit of BMT as a treatment for skeletal disorders of Hurler syndrome is limited by the poor penetration of musculoskeletal tissues by leukocyte-derived enzymes. In another series, five of eight patients with MPS underwent surgery for CTS one to nine years after bone marrow transplantation [21]. In the present series, one child with Hurler syndrome (MPS I) had undergone BMT at age 17 months but developed CTS by age 5 years, and four other affected children had been on enzyme replacement therapy for 1 to 6 years. Enzyme therapy started later in the course of the disease does not completely prevent bone disease in MPS but may slow its progression [22]. Enzyme replacement therapy with recombinant idursulfase is commonly used to treat Hunter syndrome (MPS II). In a randomised, placebo-controlled clinical trial, intravenous administration of idursulfase to 32 patients was associated with significant improvement in pulmonary function, decreased liver and spleen volumes, increased growth velocity, mild improvement with joint mobility, and reduction in urinary glycosaminoglycans [23]. However, it did not show any benefit in cognitive and behavioural manifestations of MPS. The study did not address the incidence of CTS in that series. The recent guidelines for enzyme replacement therapy in Hunter syndrome do not include data on its effect on prevention of CTS [24]. Future studies should systematically address the impact of early diagnosis and treatment of MPS with bone marrow transplantation or enzyme replacement therapy on the evolution of carpal tunnel syndrome. For the moment, regular screening for CTS is important even in those receiving these treatments.
Treatment of CTS mainly involves surgical decompression of the median nerve complemented by physiotherapy and splinting. The standard technique of median nerve decompression involves open division of the flexor retinaculum through a mid-palmar skin incision extended across the wrist crease, followed by complete exposure and release of the median nerve, with or without exploration of the thenar branch. Neurolysis of the median nerve, in addition to decompression, is advised by some authors [25], but a recent comparative study showed no additional long-term benefit from neurolysis [26]. The main histopathological feature of MPS-related CTS is the large quantity of glycosaminoglycans deposited within the flexor retinaculum, causing compressive injury to the median nerve. Direct damage to the nerve or its myelin sheath by glycosaminoglycan deposition has not been identified to date [5, 7]. This suggests that surgical technique plays a limited role in preventing recurrence of median nerve compression. Various authors have studied outcomes of surgical median nerve decompression in the MPS syndromes. Most have reported improved post-operative hand function and symptoms, with or without normalisation of nerve conduction studies [19, 27]. In a series of 48 patients with MPS and CTS, Haddad and colleagues reported improved hand function in all patients after surgery, particularly those with type II MPS [5]. Some authors have noted that early carpal tunnel release may prevent permanent nerve injury [28, 6]. Having discussed the importance of early screening and surgical intervention, none of the previous reports have recommended ideal ages for screening for CTS in this population.
One of the limitations of this study was that only symptomatic patients were screened with nerve conduction studies for presence of median neuropathy at the wrist. We cannot comment on the frequency of median neuropathy in patients without symptoms or signs suggestive of this condition.
A methodological issue with this study is that historically, in this centre, mid-palmar values were measured for sensory and motor studies. Normal values for these studies are not available in children; hence, the values recorded in the subjects studied were compared with established norms for digital studies. Because these are recorded over a longer distance, they should be associated with greater distal latencies. However, in this series, patients distal latencies were prolonged even in comparison with norms for digital studies, demonstrating the severity of the abnormalities in the subjects studied. Future studies will include establishment of normal values for palmar studies in children.